Ciguatera fish poisoning
disease diseaseOn this page
Also known as ciguateraciguatera fish Poisoningsciguatera poisoningciguatera Poisoningsciguatoxin causing toxic effectpoisoning, ciguaterapoisoning, ciguatera fishPoisonings, ciguateraPoisonings, ciguatera fish
Summary
Ciguatera fish poisoning (MONDO:0043230) is a disease and 1 clinical trial. A subtype of poisoning — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 1
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | ciguatera fish poisoning |
| Mondo ID | MONDO:0043230 |
| EFO | EFO:1001291 |
| MeSH | D036841 |
| ICD-10-CM | T61.0 |
| SNOMED CT | 241774007 |
| Is cancer (heuristic) | no |
Also known as: ciguatera · ciguatera fish poisoning · ciguatera fish Poisonings · ciguatera poisoning · ciguatera Poisonings · ciguatoxin causing toxic effect · poisoning, ciguatera · poisoning, ciguatera fish · Poisonings, ciguatera · Poisonings, ciguatera fish
Disease family
This is a subtype of poisoning. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › poisoning › ciguatera fish poisoning
Related subtypes (58): toxic oil syndrome, infantile mercury poisoning, ketamine-induced biliary dilatation, manganese poisoning, cyanide-induced parkinsonism, colchicine poisoning, methanol poisoning, ethylene glycol poisoning, paraquat poisoning, lead poisoning, mercury poisoning, acute opioid poisoning, acute tricyclic antidepressant poisoning, acute poisoning by drugs with membrane-stabilizing effect, snakebite envenomation, paracetamol poisoning, cyanide poisoning, scorpion envenomation, argyria, acute ackee fruit intoxication, cocaine intoxication, systemic monochloroacetate poisoning, water intoxication, cassavism, formaldehyde poisoning, heavy metal poisoning, abacavir toxicity, allopurinol toxicity, codeine toxicity, efavirenz toxicity, flucloxacilline toxicity, isoniazid toxicity, raltegravir toxicity, voriconazole toxicity, curariform drugs toxicity, statin toxicity, phenytoin or carbamazepine toxicity, letrozole toxicity, ricin poisoning, ivermectin toxicity, belinostat toxicity or dose selection, toxicity to dolutegravir, mycotoxicosis, lathyrism, cadmium poisoning, phenytoin toxicity, nerve agent poisoning, local anesthetic poisoning, fire ant poisoning, aflatoxicosis, black widow spider envenomation, platinum-induced ototoxicity, carbon monoxide poisoning, organophosphate poisoning, sulfur mustard poisoning, cardiac glycoside intoxication, monochloroacetic acid poisoning, chemotherapy-induced toxicity
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated or in trials for this disease
No drug has an approved disease-direct ChEMBL indication for this disease.
1 drug in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.
| Drug | Highest phase |
|---|---|
| Mannitol | Phase 3 |
Clinical trials & evidence
Clinical trials
Clinical trials: 1.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06133400 | Not specified | COMPLETED | Mapping the Health Status of the Population of French Polynesia: the MATAEA Project |
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.